Top Page
Livzon Pharmaceutical Group
(OTC:1513)
Livzon Pharmaceutical Group (1513) vs. S&P 500 (SPY)
Livzon Pharmaceutical Group Business Overview & Revenue Model
Livzon Pharmaceutical Group Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 11.81B | 12.43B | 12.63B | 12.06B | 10.52B | Gross Profit |
| 7.73B | 7.66B | 8.17B | 7.81B | 6.85B | EBIT |
| 2.84B | 2.42B | 2.35B | 2.27B | 2.50B | EBITDA |
| 3.47B | 3.33B | 3.08B | 2.77B | 2.91B | Net Income Common Stockholders |
| 2.06B | 1.95B | 1.91B | 1.78B | 1.71B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 10.92B | 11.41B | 10.52B | 9.33B | 9.98B | Total Assets |
| 24.46B | 25.04B | 24.86B | 22.37B | 20.59B | Total Debt |
| 3.93B | 3.48B | 3.62B | 2.69B | 1.93B | Net Debt |
| ― | -7.84B | -6.79B | -6.45B | -8.02B | Total Liabilities |
| 9.55B | 10.28B | 9.93B | 8.06B | 6.95B | Stockholders Equity |
| 13.86B | 14.04B | 13.88B | 13.00B | 12.11B |
| Cash Flow | Free Cash Flow | |||
| 2.41B | 2.43B | 1.83B | 593.23M | 1.51B | Operating Cash Flow |
| 2.98B | 3.25B | 2.77B | 1.90B | 2.16B | Investing Cash Flow |
| ― | -708.37M | ― | ― | ― | Financing Cash Flow |
| ― | ― | ― | ― | ― |
Livzon Pharmaceutical Group Technical Analysis
Livzon Pharmaceutical Group Peers Comparison
Livzon Pharmaceutical Group Corporate Events
Livzon Pharmaceutical Group Inc. has released its unaudited financial results for the first quarter of 2025, reporting a slight decrease in operating income by 1.92% compared to the same period last year. However, the company saw an increase in net profit attributable to shareholders by 4.75%, indicating improved profitability despite a decline in net cash flow from operating activities by 21.59%. The company’s total assets and owners’ equity also showed marginal growth, reflecting a stable financial position.
Livzon Pharmaceutical Group Inc. has announced its annual general meeting for 2024, scheduled for May 29, 2025, in Zhuhai, China. The meeting will address several key resolutions, including the approval of the 2024 work reports, financial accounts, and annual report, as well as the re-appointment of Grant Thornton as the company’s auditor. Additionally, the meeting will consider the 2024 annual profit distribution plan, which proposes a cash dividend of RMB11.00 per 10 shares, and the renewal of the company’s A Shares Repurchase Scheme. These resolutions are significant for stakeholders as they outline the company’s financial strategy and governance for the upcoming year.
Livzon Pharmaceutical Group Inc. has announced a meeting for its H shareholders to discuss and approve the renewal of the repurchase scheme for its A shares and to grant a mandate to the Board for repurchasing H shares. This move is aimed at optimizing the company’s capital structure and enhancing shareholder value, subject to regulatory approvals and compliance with applicable laws.
Livzon Pharmaceutical Group Inc. announced the cancellation of share options under its 2022 Share Options Incentive Scheme. The cancellation affects a total of 6,667,795 share options that were not exercised due to unmet performance targets and expiration. This move concludes the company’s current share options under the First Grant and the Reserved Grant, potentially impacting the company’s incentive strategies and shareholder interests.
Livzon Pharmaceutical Group Inc. has announced an update regarding its final cash dividend for the year ended December 31, 2024. The dividend, set at RMB 11 per 10 shares, will be approved by shareholders on May 29, 2025, with an ex-dividend date of June 13, 2025, and a payment date of July 11, 2025. The announcement includes details on withholding tax rates applicable to different shareholder categories, indicating a 10% tax for non-resident enterprises and a 20% tax for resident individuals. This update reflects Livzon’s commitment to shareholder returns and provides clarity on the dividend distribution process, potentially impacting investor relations and market perception.
Livzon Pharmaceutical Group Inc. announced the resignation of Mr. Yang Daihong from his position as vice president due to a work adjustment. Despite his resignation, Mr. Yang will continue to hold other roles within the company, and his departure is not expected to impact the company’s operations. The board expressed gratitude for Mr. Yang’s diligent service during his tenure.
Livzon Pharmaceutical Group Inc. announced the appointment of Mr. Xu Xiao as the vice president responsible for production operations. Mr. Xu, with extensive experience within the company and a strong educational background in pharmaceutics and engineering, is expected to enhance the company’s operational capabilities. This appointment reflects Livzon’s strategic focus on strengthening its leadership team to improve production efficiency and maintain its competitive position in the pharmaceutical industry.
Livzon Pharmaceutical Group Inc. has announced a board meeting scheduled for April 23, 2025, to review and approve the company’s unaudited quarterly results for the first quarter of 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting stakeholders and market positioning.
Livzon Pharmaceutical Group Inc. announced the resignation of Mr. Yang Liang from his position as vice president and all other roles within the company and its subsidiaries, effective immediately. His departure, due to personal career development reasons, is not expected to impact the company’s operations. The board expressed gratitude for Mr. Yang’s diligent service and confirmed there are no disagreements or issues to report to shareholders.
Livzon Pharmaceutical Group has clarified details regarding its capital contribution to LivzonBio, correcting previous statements about the nature of the shares and equity interest involved. The clarification indicates that the company subscribed for increased registered capital, securing an 18.85% equity interest in LivzonBio, which may impact its financial positioning and stakeholder interests.
Livzon Pharmaceutical Group Inc. has announced its audited financial results for the year ending December 31, 2024. The release of these results, which comply with the Hong Kong Stock Exchange’s listing requirements, provides stakeholders with insights into the company’s financial performance and strategic positioning. The full annual report will be available in April 2025, offering further details on the company’s operations and governance.
Livzon Pharmaceutical Group has announced a capital contribution of RMB1 billion to its subsidiary, LivzonBio, increasing its stake from 60.23% to 66.54%. This strategic move is part of a connected transaction under Hong Kong Listing Rules, aimed at strengthening LivzonBio’s financial position and enhancing the company’s influence in the biotech sector.
Livzon Pharmaceutical Group Inc. has announced a final ordinary cash dividend of RMB 11 per 10 shares for the financial year ending December 31, 2024. This announcement reflects the company’s financial health and commitment to delivering shareholder value, although specific details regarding the payment date and exchange rates are yet to be disclosed.
Livzon Pharmaceutical Group Inc. has announced changes in its accounting policies in line with the latest requirements from the Ministry of Finance. These changes, effective from January 2024, involve the classification of liabilities and disclosure of supplier financing arrangements, impacting how the company reports its financial obligations and liquidity risks. These adjustments are expected to enhance transparency and compliance with updated accounting standards, potentially affecting stakeholders’ understanding of the company’s financial health.
Livzon Pharmaceutical Group Inc. has announced that its wholly-owned subsidiary, Livzon Group Limin Pharmaceutical Manufacturing Factory, received approval from the National Medical Products Administration for the market launch of its Progesterone Injection. This product, designed for supplementary progesterone therapy in assisted reproductive technology, offers a water-soluble formulation that enhances patient convenience and adherence by allowing self-administration and reducing adverse reactions.
Livzon Pharmaceutical Group Inc. has announced that its board of directors will meet on March 26, 2025, to review and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the recommendation of a final dividend, which could impact the company’s financial strategy and shareholder returns.
Livzon Pharmaceutical Group Inc. has received clinical trial approval from the National Medical Products Administration for JP-1366, a new potassium-competitive acid blocker for injection. This approval allows the company to proceed with trials targeting peptic ulcer bleeding, further extending its research on JP-1366, which is already undergoing trials for reflux esophagitis. This step is expected to enhance Livzon’s industry positioning by expanding its portfolio of gastrointestinal treatments.